NCT05177835: Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
- State
- Under way
- Phase
- Phase 2
- People
- 203 planned
- Started
- 3 Dec 2021
- Primary completion
- Mar 2028
- Arms
- ABX464 -25mg
- Results
- None posted
- 3 Dec 2021: Trial started
- 5 Jan 2022: Trial registered